RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
+6.62%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$6.76B
AUM Growth
+$6.76B
(-4.8%)
Cap. Flow
-$348M
Cap. Flow
% of AUM
-5.15%
Top 10 Holdings %
Top 10 Hldgs %
43.88%
Holding
93
New
7
Increased
14
Reduced
55
Closed
7
Top Buys
| 1 |
VERV
Verve Therapeutics
VERV
|
$117M |
| 2 |
The Beauty Health Co
SKIN
|
$73.4M |
| 3 |
ZY
Zymergen Inc. Common Stock
ZY
|
$60.9M |
| 4 |
ONEM
1Life Healthcare, Inc. Common Stock
ONEM
|
$36.5M |
| 5 |
Lifestance Health
LFST
|
$35M |
Top Sells
| 1 |
Medtronic
MDT
|
$116M |
| 2 |
Zentalis Pharmaceuticals
ZNTL
|
$95.5M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$85.8M |
| 4 |
Beam Therapeutics
BEAM
|
$61.8M |
| 5 |
Biogen
BIIB
|
$45.6M |
Sector Composition
| 1 | Healthcare | 95.41% |
| 2 | Consumer Staples | 1.58% |
| 3 | Financials | 0.69% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$120M
| $1.12B | 16.64% | 12,957,222 | – | – |
|
|
IGMS
2
DELISTED
IGM Biosciences
IGMS
| $285M | 4.22% | 3,425,455 | – | – |
|
|
3
Beam Therapeutics
BEAM
$1.66B
| $264M | 3.91% | 2,052,506 -480,017 | -19% | -$61.8M |
|
4
argenx
ARGX
$43.6B
| $238M | 3.52% | 790,282 -59,563 | -7% | -$17.9M |
|
5
Amicus Therapeutics
FOLD
$2.34B
| $201M | 2.97% | 20,799,303 -314,811 | -1% | -$3.03M |
|
|
ALLK
6
DELISTED
Allakos
ALLK
| $189M | 2.8% | 2,216,996 -202,422 | -8% | -$17.3M |
|
7
ADC Therapeutics
ADCT
$345M
| $183M | 2.71% | 7,522,029 +213,611 | +3% | +$5.2M |
|
8
Shattuck Labs
STTK
$47M
| $163M | 2.41% | 5,619,914 | – | – |
|
9
Replimune Group
REPL
$422M
| $161M | 2.38% | 4,191,512 +73,300 | +2% | +$2.82M |
|
|
NVTA
10
DELISTED
Invitae Corporation
NVTA
| $157M | 2.32% | 4,647,393 -204,770 | -4% | -$6.91M |
|
|
DCPH
11
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $155M | 2.3% | 4,244,721 -106,923 | -2% | -$3.91M |
|
12
Jazz Pharmaceuticals
JAZZ
$7.75B
| $153M | 2.26% | 860,101 +30,942 | +4% | +$5.5M |
|
|
MDVL
13
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $144M | 2.13% | 11,724,726 | – | – |
|
14
Krystal Biotech
KRYS
$4.27B
| $141M | 2.09% | 2,072,132 +12,000 | +0.6% | +$816K |
|
|
OSH
15
DELISTED
Oak Street Health, Inc.
OSH
| $135M | 2% | 2,302,653 -627,758 | -21% | -$36.8M |
|
16
Kymera Therapeutics
KYMR
$2.95B
| $123M | 1.82% | 2,531,508 -71,631 | -3% | -$3.47M |
|
|
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
| $122M | 1.8% | 771,385 -165,660 | -18% | -$26.2M |
|
|
VERV
18
DELISTED
Verve Therapeutics
VERV
| $117M | 1.73% | +1,936,530 | New | +$117M |
|
|
19
The Beauty Health Co
SKIN
$264M
| $107M | 1.58% | 6,353,246 +4,370,497 | +220% | +$73.4M |
|
20
Celldex Therapeutics
CLDX
$1.47B
| $101M | 1.49% | 3,012,081 -375,707 | -11% | -$12.6M |
|
21
Atara Biotherapeutics
ATRA
$84.6M
| $100M | 1.48% | 6,449,577 -435,656 | -6% | -$6.77M |
|
|
NVRO
22
DELISTED
NEVRO CORP.
NVRO
| $98.6M | 1.46% | 594,732 +77,937 | +15% | +$12.9M |
|
23
DexCom
DXCM
$29.5B
| $98.4M | 1.46% | 230,558 +8,100 | +4% | +$3.46M |
|
24
LivaNova
LIVN
$3.08B
| $93.5M | 1.38% | 1,111,684 -8,146 | -0.7% | -$685K |
|
25
Pliant Therapeutics
PLRX
$101M
| $91.9M | 1.36% | 3,156,401 -50,792 | -2% | -$1.48M |
|